CA2951420A1 - Methods for treating pruritus - Google Patents

Methods for treating pruritus Download PDF

Info

Publication number
CA2951420A1
CA2951420A1 CA2951420A CA2951420A CA2951420A1 CA 2951420 A1 CA2951420 A1 CA 2951420A1 CA 2951420 A CA2951420 A CA 2951420A CA 2951420 A CA2951420 A CA 2951420A CA 2951420 A1 CA2951420 A1 CA 2951420A1
Authority
CA
Canada
Prior art keywords
day
nalbuphine
pruritus
sustained release
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2951420A
Other languages
English (en)
French (fr)
Inventor
Thomas Sciascia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevi Therapeutics Inc
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of CA2951420A1 publication Critical patent/CA2951420A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2951420A 2014-06-13 2015-06-12 Methods for treating pruritus Abandoned CA2951420A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011936P 2014-06-13 2014-06-13
US62/011,936 2014-06-13
PCT/US2015/035650 WO2015192071A1 (en) 2014-06-13 2015-06-12 Methods for treating pruritus

Publications (1)

Publication Number Publication Date
CA2951420A1 true CA2951420A1 (en) 2015-12-17

Family

ID=54834447

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2951420A Abandoned CA2951420A1 (en) 2014-06-13 2015-06-12 Methods for treating pruritus

Country Status (12)

Country Link
US (2) US20150359789A1 (enExample)
EP (1) EP3154546A4 (enExample)
JP (1) JP2017517553A (enExample)
KR (1) KR20170016983A (enExample)
CN (1) CN106535897A (enExample)
AU (1) AU2015274327A1 (enExample)
BR (1) BR112016029236A2 (enExample)
CA (1) CA2951420A1 (enExample)
IL (1) IL249475A0 (enExample)
MX (1) MX2016016404A (enExample)
RU (1) RU2017101102A (enExample)
WO (1) WO2015192071A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2017120468A1 (en) * 2016-01-06 2017-07-13 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CA3017374A1 (en) * 2016-03-21 2017-09-28 Trevi Therapeutics, Inc. Treatment of uremic pruritus
WO2018081273A1 (en) * 2016-10-25 2018-05-03 Trevi Therapeutics, Inc. Treatment of prurigo nodularis
KR20200138730A (ko) * 2018-03-29 2020-12-10 루모사 테라퓨틱스 캄파니 리미티드 가려움증 치료용 조성물 및 방법
AU2019301134A1 (en) * 2018-07-11 2021-01-21 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
CN118512451A (zh) * 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620224C (en) * 2005-08-24 2015-11-24 Penwest Pharmaceuticals Company Sustained release formulations of nalbuphine
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
WO2008128892A1 (en) * 2007-04-23 2008-10-30 Symrise Gmbh & Co. Kg Polyethylene glycol esters and cosmetic and/or dermatological preparations
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) * 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus

Also Published As

Publication number Publication date
BR112016029236A2 (pt) 2017-11-07
CN106535897A (zh) 2017-03-22
WO2015192071A1 (en) 2015-12-17
AU2015274327A1 (en) 2017-01-05
KR20170016983A (ko) 2017-02-14
JP2017517553A (ja) 2017-06-29
EP3154546A1 (en) 2017-04-19
RU2017101102A (ru) 2018-07-16
MX2016016404A (es) 2017-11-30
RU2017101102A3 (enExample) 2019-01-28
US20150359789A1 (en) 2015-12-17
IL249475A0 (en) 2017-02-28
EP3154546A4 (en) 2018-01-10
US20190099416A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
AU2018214098B2 (en) Methods for treating pruritus
US20250032480A1 (en) Methods for treating pruritus
US8987289B2 (en) Methods for treating pruritus
US20190099416A1 (en) Methods for treating pruritus
US8637538B1 (en) Methods for treatment of pruritis
US20170216277A1 (en) Therapeutic use of nalbuphine without aquaretic effects
EP3432871B1 (en) Treatment of uremic pruritus
CA3105680A1 (en) Treatment of the pruritic symptoms of liver disease
HK40013011A (en) Methods for treating pruritus
HK1215541B (en) Methods for treating pruritus

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123